For patients with favorable-risk AML, such as those with CBF-AML or NPM1 mutations without high allelic burden FLT3-ITD mutations, consolidative therapy often involves high-dose cytarabine to reduce the risk of relapse and improve outcomes [5,6]. The gene discussed is FLT3; the disease is acute myeloid leukemia.